Thanks @Shaunbra some more digging and I think all but one author is now known.
Assuming the paper follows the rule of significance of contributions, then my guess is the paper will lead with bile duct cancer (Li & Shields). Given the weight and grouping of authors I still think a new & notable result in lung/thoracic looks very likely. I'm not ruling out something from left field, pancreatic cancer does pop up throughout so it could take the lead from bile duct cancer.
There's a mixed bag of remaining authors and excluding Imugene staff, these come from the fields of head/neck, Melanoma, pancreatic, breast, gynaecological and others. Assuming of course our web trawling has correctly identified the authors.
Here's the updated author list:
Prof Donghui Li Ph.D., Professor, Department of Gastrointestinal (GI) Medical Oncology - Research, MD Anderson Cancer Center, Houston, TX. Numerous articles on cholangiocarcinoma & pancreatic cancer.
Dr Anthony F Shields M.D., Ph.D., gastrointestinal oncology at Karmanos Cancer Center in Detroit. Works in the area of imaging and anticancer drug assessment.
Dr Hirva Mamdani M.D., thoracic oncology, particularly lung cancer and mesothelioma at Karmanos Cancer Center, Detroit.
Dr Patrick M Travis M.D., Oncologist, Arkansas
A/Prof Gavin M. Wright MBBS, FRACS, Ph.D., thoracic surgeon with interest in lung cancer research, St Vincent's Hospital, Melbourne
Wallace Akerley M.D., Director of Thoracic Oncology, Huntsman Cancer Institute at the University of Utah. Greater than 30 years experience as a principal investigator on numerous clinical research trials who actively cares for patients with lung cancer. Director of the Lung Cancer Disease Center of Excellence at HCI and member of the NCCN's Steering Committee for Small Cell Lung Cancer Panel and NSCLC Panel.
Dr Alexander I. Spira, M.D., Ph.D.,FACP, Co-Director, VCS Research Institute, Director, Thoracic and Phase I Program, Clinical Assistant Professor, Johns Hopkins. Dr Spira specializes in lung malignancies such as pleural mesothelioma.
Prof Gregory A. Daniels M.D., Ph.D, Oncologist, University of California, San Diego. Specialises in head & neck cancers, melanoma.
Prof Jaime R Merchan, M.D., Tenured Professor of Medicine, University of Miami Miller School of Medicine. Specialises in renal cell carcinoma, oncolytic virotherapy.
Dr Amanika Kumar, M.D. Gynecologic Oncologist at the Mayo Clinic in Minnesota.
Prof. Elgene Lim Ph.D,. Medical oncologist and researcher with a focus on breast cancer research and treatment, and the Principal Cancer Theme Lead at the Faculty of Medicine, UNSW Sydney, and the inaugural National Breast Cancer Foundation Endowed Chair
Colt Egelston Ph. D., Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center. Colt does research in Immunology and Clinical Immunology with a focus on T cell functionality and antigen specificity in various cancer malignancies.
Oscar Colunga Flores. Department of Immune-Oncology, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA.
Dr Sarah Hamilton M.D., FRCPC, Dr. Hamilton is a radiation oncologist at BC Cancer – Vancouver and clinical assistant professor at UBC. She has a clinical focus in treating gynecologic cancer and head and neck cancer.
Dr Juanito Austria M.D.?, unable to identify for certain, if this is the person then San Francisco based "internist" whatever that is.
Amanda Seiz, Imugene, Sydney
Sharon Yavrom, Imugene, Sydney
Dr Seymour Fein M.D., Imugene, Oncolytic Viral therapy medical director
Dr John Byon M.D., Imugene, SVP Clinical Development.
Dr Paul Woodard M.D, Imugene, CMO.
Grey A. Wilkinson, Imugene, Canada, clinical researcher.
A/Prof Jennifer Leddon, M.D., Ph.D, University of Cincinnati. Clinical interests oncology, lung cancer.
IMU Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
(20min delay)
